News

News

Press releases

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the News

Xconomy
Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg
Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets

Twitter

@KynTherapeutics
Kyn has partnered with @Celgene to advance two of our immuno-oncology programs targeting critical… http://ag4kiXkf5L

@KynTherapeutics
Our lead clinical program targets the EP4 receptor in the prostaglandin E2 (PGE2) immunosuppressive axis in the tum… http://D4CRi2DP4T

@KynTherapeutics
It's #WorldCancerDay. At Kyn, we drive our field of #immunooncology research forward towards therapies that improve… http://lNJRU8CjyC

@KynTherapeutics
We're proud to welcome Doug Carlson, a highly experienced healthcare financial executive, as our chief financial of… http://7O8oOAtNTx

Media contact

Tom Donovan
Ten Bridge Communications
857-559-3397
tom@tenbridgecommunications.com

Alerts

Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us

1-857-273-8343

Email us

info@kyntherapeutics.com

Friend us

LinkedIn